Investor Lawsuit Targets BioAge Labs Following Disrupted Drug Trial and Stock Plunge

New York — A prominent securities law firm, Bleichmar Fonti & Auld LLP, has recently initiated a lawsuit against BioAge Labs, Inc., a company listed on NASDAQ under the ticker BIOA, along with some of its top executives. The legal action alleges potential breaches of federal securities laws linked to the company’s initial public offering. As part of the case, which is filed under the docket Soto v. BioAge Labs, Inc., et al., No. 25-cv-196, plaintiffs must file their petitions by March 10, 2025, to be considered as lead plaintiffs. The filed complaint highlights issues … Read more

Opportunity Opens for BIOA Investors to Lead in BioAge Labs Securities Fraud Case with Schall Law Firm Support

Los Angeles, CA – Investors who have placed their funds in BioAge Labs, Inc. shares are being invited to potentially lead a class action lawsuit alleging securities fraud, with legal support from the Schall Law Firm. This development follows claims that the biotechnology company may have violated securities laws, possibly impacting investor trust and financial losses. The lawsuit centers on accusations that BioAge Labs raised investor expectations with purportedly misleading statements about its business prospects and operations. Among the concerns raised are issues related to the public disclosures made by the company, which allegedly provided … Read more